Stay updated on Pembrolizumab in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to pembrolizumab with rituximab or obinutuzumab in treating patients with recurrent or refractory follicular lymphoma or diffuse large B cell lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:09.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' The new description provides examples of eligibility criteria, such as a person's general health condition or prior treatments, and includes a link for general information about clinical research.
    Difference
    50%
    Check dated 2024-05-22T21:21:23.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:44:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Clinical Trial page.